The Research Animal Support Facility (RASF) has been a shared resource since the original CCSG was awarded in 1975 and exists to support ongoing clinical and basic cancer research involving laboratory animals at MDACC. The RASF has components located in Houston at MDACC (2 campuses), and in Smithville in the Department of Carcinogenesis. All animal facilities are accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International, have Animal Welfare Assurance approval (A3343-01), and are registered as research animal facilities with the United States Department of Agriculture (USDA) (74-R-065). The Research Animal Support Facility Houston (RASFH) is directed by Peggy T. Tinkey, D.V.M. The RASFH encompasses approximately 99,089 sq. ft. of space and provides housing, procedure space, veterinary care, and quality assurance programs for animals used in cancer research. Clinical, surgical, imaging, radiation therapy, and pathology laboratory facilities and services are provided. Existing technical services have been extended to the South Campus facility, and new services added since the last CCSG renewal include computerized animal pedigree and medical history applications, preclinical toxicology services, and increased transportation services. New equipment includes automated multi-species hematology and chemistry analyzers, patient monitoring systems, automated bedding dispensing systems and waste containers, cargo van, and 100 ventilated rodent rack/cage systems. The RASFH has 122 personnel, which includes 11 veterinarians, 2 associate directors, 1 administrator, 2 section managers, 1 project manager, 10 laboratory personnel, 77 animal care personnel, and 17 clerical/support staff. Dr. Tinkey coordinates the daily operations of the RASFH. Five faculty veterinarians direct the 5 service sections that provide facilities, equipment, and services to research animal users. Funding for the RASFH is currently provided by the CCSG (6%), user fees (39%), institutional support (53%) and other funds (2%). In the past 5 years, the RASFH has been used by 319 investigators supporting 20 different CCSG programs. Peer-reviewed investigators represent 92% of the RASFH user utilization. The majority of animals used are genetically engineered mice. In the past 5 years, the daily average cage counts increased 52%, from 13,243 cages in 2002-03 to 20,132 cages of animals in 2006-07. Future plans include renovation and expansion of the South Campus animal facility, and upgrading and implementing computer applications for business operations and preclinical drug development. Additionally, RASF-Houston and Smithville have jointly submitted a startup proposal to develop a Mutant Mouse Pathology Service to serve all MDACC investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-35
Application #
8144401
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
35
Fiscal Year
2010
Total Cost
$1,285,623
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Abaza, Yasmin; M Kantarjian, Hagop; Faderl, Stefan et al. (2018) Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93:91-99
Ok, Chi Young; Loghavi, Sanam; Sui, Dawen et al. (2018) Persistent IDH1/2 mutation in remission can predict relapse in patients with acute myeloid leukemia. Haematologica :
Ajani, Jaffer A; Estrella, Jeannelyn S; Chen, Qiongrong et al. (2018) Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Br J Cancer 118:52-61
Gharpure, Kshipra M; Pradeep, Sunila; Sans, Marta et al. (2018) FABP4 as a key determinant of metastatic potential of ovarian cancer. Nat Commun 9:2923
Khan, Maliha; Muzzafar, Tariq; Kantarjian, Hagop et al. (2018) Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia. Ann Hematol 97:1183-1191
Somaiah, Neeta; Beird, Hannah C; Barbo, Andrea et al. (2018) Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget 9:19891-19899
Sandulache, Vlad C; Michikawa, Chieko; Kataria, Pranav et al. (2018) High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. Clin Cancer Res 24:1727-1733
Puli, Oorvashi Roy; Danysh, Brian P; McBeath, Elena et al. (2018) The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia 20:1121-1134
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360

Showing the most recent 10 out of 12418 publications